Axe Compute Inc. logo

Axe Compute Inc. (S1K0)

Market Open
13 Aug, 20:00
XDUS XDUS
7. 10
+0.2
+2.8986%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
6.9
Previous Close
Add Transaction
Day Range
6.85 7.1
Year Range
1.05 8.2
Want to track S1K0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

S1K0 trading today higher at €7.1, an increase of 2.8986% from yesterday's close, completing a monthly decrease of -0.6993% or -€0.05. Over the past 12 months, S1K0 stock gained 22.4138%.
S1K0 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XDUS (EUR).

S1K0 Chart

Axe Compute Inc. (S1K0) FAQ

What is the stock price today?

The current price is €7.10.

On which exchange is it traded?

Axe Compute Inc. is listed on XDUS.

What is its stock symbol?

The ticker symbol is S1K0.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Axe Compute Inc. ever had a stock split?

No, there has never been a stock split.

Axe Compute Inc. Profile

Transportation Infrastructure Industry
Industrials Sector
Christopher Miglino CEO
XDUS Exchange
- ISIN
US Country
14 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Axe Compute Inc. is a knowledge and science-driven company focusing on the application of artificial intelligence (AI) to advance the discovery and development of cancer therapies. Established in 2002 and headquartered in Pittsburgh, Pennsylvania, the company operates primarily through two segments: Pittsburgh and Eagan. The Pittsburgh segment leverages a proprietary biobank containing over 150,000 tumor samples to enhance its AI applications, while also developing proprietary 3D culture models that support drug development initiatives. The Eagan segment specializes in the production of the FDA-cleared STREAMWAY System and related products, which are designed for the automated management of medical fluid waste and streamlined patient-to-drain fluid disposal. In addition, Axe Compute maintains a strategic collaboration with Every Cure to identify and prioritize drugs suitable for repurposing, facilitating progress in oncology research and treatments. The company, originally known as Predictive Oncology Inc., rebranded as Axe Compute Inc. in December 2025.

Products and Services

  • AI Applications for Cancer Therapy Development

    This service harnesses the power of artificial intelligence to analyze data from its extensive biobank of tumor samples, aiding researchers in uncovering new therapeutic possibilities and enhancing the precision of oncology treatments.

  • Proprietary Biobank

    Ake Compute Inc. houses a comprehensive biobank of over 150,000 tumor samples, which serves as a critical resource in supporting research initiatives and AI applications for drug development and discovery in oncology.

  • 3D Culture Models

    The development of proprietary 3D culture models represents a cutting-edge approach in drug testing and development, providing a more accurate representation of human tumor environments and thereby facilitating better therapeutic outcomes.

  • STREAMWAY System

    This FDA-cleared system is designed for the automated management of medical fluid waste, automating the processes of disposal and enhancing safety and efficiency in medical settings.

  • Medical Fluid Disposal Products

    Axe Compute offers associated products that support the proper handling and disposal of medical fluids, ensuring compliance with safety regulations and enhancing operational workflows in healthcare facilities.

  • Drug Repurposing Collaboration

    Through its strategic partnership with Every Cure, Axe Compute aims to identify and reprioritize existing drugs, optimizing their use for new therapeutic applications, particularly in cancer treatment, thereby accelerating the pathway to effective therapies.

Contact Information

Address: 91 43rd Street
Phone: 412 432 1500